| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON.15.292 |
| P698 | PubMed publication ID | 26616915 |
| P50 | author | Elaine M Taylor | Q42585745 |
| Howard D Lindsay | Q73875722 | ||
| P2093 | author name string | Howard D Lindsay | |
| Elaine M Taylor | |||
| P2860 | cites work | Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells | Q39490308 |
| Failure of Origin Activation in Response to Fork Stalling Leads to Chromosomal Instability at Fragile Sites | Q39512958 | ||
| Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. | Q39559122 | ||
| Signatures of mutation and selection in the cancer genome | Q39737975 | ||
| The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. | Q39755271 | ||
| Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response | Q39822052 | ||
| Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. | Q39947737 | ||
| Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity | Q40603124 | ||
| DNA damage tolerance: when it's OK to make mistakes | Q41860261 | ||
| Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity | Q42713005 | ||
| Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. | Q42745810 | ||
| Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy | Q42862104 | ||
| Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic cata | Q45064006 | ||
| Dynamics of DNA replication in mammalian somatic cells: nucleotide pool modulates origin choice and interorigin spacing | Q51834619 | ||
| Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. | Q53284482 | ||
| Mechanisms of change in gene copy number | Q22122003 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging | Q22337238 | ||
| Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. | Q24522744 | ||
| Mutational processes molding the genomes of 21 breast cancers | Q24620915 | ||
| Massive genomic rearrangement acquired in a single catastrophic event during cancer development | Q24631164 | ||
| Complex landscapes of somatic rearrangement in human breast cancer genomes | Q24631412 | ||
| Replication Stress: A Lifetime of Epigenetic Change | Q26785908 | ||
| Chromothripsis from DNA damage in micronuclei. | Q27316519 | ||
| Increased mutagenesis and unique mutation signature associated with mitotic gene conversion | Q27934880 | ||
| Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer | Q28239595 | ||
| Genomic instability--an evolving hallmark of cancer | Q28274009 | ||
| CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy | Q28300482 | ||
| Non-transcriptional control of DNA replication by c-Myc | Q28307758 | ||
| The landscape of somatic copy-number alteration across human cancers | Q29547648 | ||
| ATR: an essential regulator of genome integrity | Q29547883 | ||
| Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions | Q29614216 | ||
| DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis | Q29614217 | ||
| An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer | Q29616732 | ||
| Epigenetics in cancer | Q29617139 | ||
| Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints | Q29617405 | ||
| Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication | Q29617915 | ||
| NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells | Q30429284 | ||
| Spontaneous slow replication fork progression elicits mitosis alterations in homologous recombination-deficient mammalian cells. | Q30565967 | ||
| A microhomology-mediated break-induced replication model for the origin of human copy number variation | Q33404060 | ||
| Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. | Q33419897 | ||
| Break-induced replication repair of damaged forks induces genomic duplications in human cells. | Q33719358 | ||
| Secondary structure formation and DNA instability at fragile site FRA16B | Q33871196 | ||
| Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation | Q34010975 | ||
| More forks on the road to replication stress recovery | Q34161464 | ||
| Chromosome catastrophes involve replication mechanisms generating complex genomic rearrangements | Q34217081 | ||
| Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. | Q34223352 | ||
| R Loops: From Transcription Byproducts to Threats to Genome Stability | Q34271508 | ||
| Chk1 is haploinsufficient for multiple functions critical to tumor suppression | Q34334239 | ||
| KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors | Q34358720 | ||
| Causes and consequences of replication stress | Q34394094 | ||
| The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition | Q34399650 | ||
| CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis | Q34449803 | ||
| Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer | Q34530885 | ||
| Coordinated degradation of replisome components ensures genome stability upon replication stress in the absence of the replication fork protection complex | Q34561912 | ||
| RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma | Q34602599 | ||
| Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells | Q34603025 | ||
| Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner | Q34676703 | ||
| An oncogene-induced DNA damage model for cancer development | Q34759268 | ||
| ATR prohibits replication catastrophe by preventing global exhaustion of RPA. | Q35051406 | ||
| Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo | Q35073758 | ||
| Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines | Q35212640 | ||
| The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle | Q35379903 | ||
| Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites | Q35751401 | ||
| Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors | Q35800291 | ||
| Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. | Q35992079 | ||
| Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes | Q36193230 | ||
| The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy | Q36289912 | ||
| CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. | Q36328196 | ||
| DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients. | Q36415115 | ||
| Transient excess of MYC activity can elicit genomic instability and tumorigenesis | Q36455522 | ||
| Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. | Q36525188 | ||
| Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells | Q36552538 | ||
| Identification of Early Replicating Fragile Sites that Contribute to Genome Instability | Q36776345 | ||
| A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. | Q36908567 | ||
| ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. | Q36941455 | ||
| Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors | Q36972697 | ||
| DNA secondary structures: stability and function of G-quadruplex structures | Q37051064 | ||
| ATR phosphorylates SMARCAL1 to prevent replication fork collapse | Q37064611 | ||
| Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development | Q37087191 | ||
| Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells | Q37099799 | ||
| CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors | Q37168650 | ||
| Diminished origin-licensing capacity specifically sensitizes tumor cells to replication stress. | Q37232780 | ||
| RNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells | Q37271812 | ||
| Cdc45 is a critical effector of myc-dependent DNA replication stress. | Q37292428 | ||
| New histone supply regulates replication fork speed and PCNA unloading | Q37441326 | ||
| Pan-cancer patterns of somatic copy number alteration | Q37666205 | ||
| CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. | Q37676283 | ||
| Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication | Q37936675 | ||
| The DNA damage response and cancer therapy | Q37977004 | ||
| Preventing replication stress to maintain genome stability: resolving conflicts between replication and transcription | Q37998652 | ||
| Translesion DNA synthesis and mutagenesis in eukaryotes | Q38086224 | ||
| Transcription-replication encounters, consequences and genomic instability | Q38095707 | ||
| DNA replication and oncogene-induced replicative stress | Q38213228 | ||
| ATM and ATR as therapeutic targets in cancer | Q38289832 | ||
| DNA replication stress as a hallmark of cancer | Q38332707 | ||
| Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion. | Q38342145 | ||
| A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer | Q38856965 | ||
| Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress | Q38936778 | ||
| ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency | Q39012252 | ||
| Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor | Q39082437 | ||
| DNA methyltransferase 1 knockdown activates a replication stress checkpoint. | Q39129505 | ||
| ERCC1 and MUS81–EME1 promote sister chromatid separation by processing late replication intermediates at common fragile sites during mitosis | Q39133182 | ||
| Replication stress links structural and numerical cancer chromosomal instability | Q39187683 | ||
| The role of PR-Set7 in replication licensing depends on Suv4-20h | Q39244779 | ||
| Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication | Q39258788 | ||
| Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress | Q39285948 | ||
| Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. | Q39294122 | ||
| Targeting radiation-resistant hypoxic tumour cells through ATR inhibition | Q39328356 | ||
| The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells | Q39338774 | ||
| A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress | Q39385211 | ||
| DNA breaks and chromosome pulverization from errors in mitosis | Q39410009 | ||
| Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. | Q39422587 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 221-237 | |
| P577 | publication date | 2015-11-30 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | DNA replication stress and cancer: cause or cure? | |
| P478 | volume | 12 |
| Q36238259 | A Model to Investigate Single-Strand DNA Responses in G1 Human Cells via a Telomere-Targeted, Nuclease-Deficient CRISPR-Cas9 System |
| Q38675646 | Cip29 is phosphorylated following activation of the DNA damage response in Xenopus egg extracts |
| Q41389205 | Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells |
| Q51765121 | Deficiency in DNA damage response of enterocytes accelerates intestinal stem cell aging in Drosophila |
| Q39076783 | Effects of Replication and Transcription on DNA Structure-Related Genetic Instability |
| Q57160183 | Exploring the links between cancer and placenta development |
| Q58595414 | Genome Instability Induced by Low Levels of Replicative DNA Polymerases in Yeast |
| Q64276181 | Identification of hub genes and therapeutic drugs in esophageal squamous cell carcinoma based on integrated bioinformatics strategy |
| Q36187661 | Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase |
| Q47938130 | MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress |
| Q41913553 | Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage |
| Q96305534 | Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability |
| Q53793587 | Targeting the replisome with transduced monoclonal antibodies triggers lethal DNA replication stress in cancer cells. |
| Q57793036 | The Impact of Replication Stress in Human Papillomavirus Pathogenesis |
| Q90402483 | The role of fork stalling and DNA structures in causing chromosome fragility |
| Q26746180 | The well-accepted notion that gene amplification contributes to increased expression still remains, after all these years, a reasonable but unproven assumption |
| Q41545189 | Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity |
Search more.